The Almac Group and Exco InTouch announced that Almac’s Clinical Technologies business unit has formed an exclusive integrated patient management alliance with Exco InTouch, a firm specializing in patient recruitment, retention, compliance, and ePRO services. The alliance will be focused on the integration of both technology and processes by both firms to deliver patient management, compliance, retention, and ePRO service offerings to sponsors of clinical trials.
The Almac-Exco InTouch offering helps to engage, retain, and enhance compliance of patients from the earliest stages of recruitment and throughout the course of a trial. Exco InTouch will work with Almac to integrate its retention and compliance technology solutions with Almac’s IXRS® technology, an integrated phone and web platform. This industry offering will allow patients to receive messages for key elements of their required study conduct using Short Message Service (SMS) text messages, emails, or phone calls. Examples of messages include reminders to attend clinic visits or to fill out patient diaries, medication prompts, notices to attend appointments in a fasted state, to return unused medication, and even encouragement messages to keep all patients motivated to participate in the clinical trial.
The Almac-Exco InTouch alliance offers sponsors the benefit of alleviating clinical trial site personnel of significant administrative burdens and activities relating to protocol compliance. Moreover, it provides biopharmaceutical firms a way to ease a patient’s journey through the clinical trial process using familiar technologies that are both popular and ubiquitous, including phone, web, text messages and email. The solution keeps patients on track during a trial and offers them an “electronic tap on the shoulder” in their native languages to help drive compliance.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Gilead Shares Final Data from Phase III MYR301 Trial of Bulevirtide in Chronic Hepatitis Delta Virus
May 7th 2025Long-term results from the study show 90% of patients with chronic HDV who achieved undetectable HDV RNA at 96 weeks of treatment remained undetectable for nearly 2 years post-treatment.